Contribute Try STAT+ Today

Ever since Amazon launched its digital pharmacy late last year, industry rivals have been worried the tech giant would steal the show. Rather than waiting to find out, they’re all scrambling to secure their spot on the stage.

Some, like Nurx and Folx, are zeroing in on underserved or specific populations, hoping to build a loyal, lifetime patient pool. Others, such as Hims, Ro, and GoodRx, are going broad: adding new telemedicine services, offering steep discounts and subscription perks, and in some cases, pitching themselves as a trustworthy, more bespoke alternative to Amazon.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.